Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024)
Ligand Pharmaceuticals (LGND) reported Raw Materials of $603000.0 for Q4 2024, up 43.57% on a YoY basis from $420000.0 in Q1 2024, and down 75.83% sequentially from $2.5 million in Q3 2024.
Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 2 years of Raw Materials data on file, last reported at $603000.0 in Q4 2024.
- For the quarter ending Q4 2024, Raw Materials rose 43.57% year-over-year to $603000.0; the trailing twelve-month figure through Dec 2024 stood at $603000.0 (up 43.57% YoY), and the FY2024 full-year result was $603000.0, up 43.57% from the prior year.
- Raw Materials declined to $603000.0 in Q4 2024, from $2.5 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $2.5 million in Q3 2024 to a low of $420000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Dec 31, 2023 | 420,000.00 |